眼科药物市场－全球产业规模、份额、趋势、竞争格局、机会及预测（按类型、药物类别、疾病适应症、分销管道、地区和竞争格局划分，2021-2031年）

全球眼药水市场预计将从 2025 年的 161.2 亿美元成长到 2031 年的 231.1 亿美元，复合年增长率为 6.19%。

眼药水是一种用于眼表的无菌液体药物，对于治疗包括青光眼、结膜炎和干眼症在内的多种眼部疾病至关重要。随着与老龄化相关的眼科疾病日益增多以及电子萤幕的广泛使用（这些因素都会加剧眼表併发症），眼药水产业蓬勃发展。根据美国验光协会 (AOA) 2024 年的数据，超过 1.04 亿美国工作年龄层每天使用电子设备超过 7 小时，这种习惯与眼部疲劳和干眼症的加剧直接相关。这持续推高了非处方和处方笺眼科护理产品的需求。

然而，眼科市场在严格的监管合规和品质保证方面面临着许多障碍。监管机构对眼科产品有严格的无菌和安全通讯协定要求，这需要复杂的生产系统和广泛的临床检验才能获得市场核准。因此，製造商必须应对高昂的合规成本和产品召回的固有风险，而产品召回会扰乱供应链并削弱消费者信心。这些监管挑战构成了重大阻碍因素，可能会延迟新配方产品上市，并限制整个产业的扩张。

市场驱动因素

数位眼疲劳和干眼症发病率的上升是全球眼药水市场的主要驱动力。现代生活方式，尤其是长时间接触电子萤幕，导致眼表疾病急剧增加，使得人们需要频繁使用人工泪液和润滑眼药水。环境压力和隐形眼镜使用量的增加进一步加剧了这一趋势，导致泪膜不稳定。製造商正在提供标靶治疗来满足这一需求，其成功体现在强劲的财务业绩上。例如，博士伦公司于2025年2月发布的「2024年第四季及全年财务表现」显示，干眼症产品的销售额已接近10亿美元，凸显了消费者对有效缓解症状的迫切需求。

同时，慢性眼科疾病的日益普遍，尤其是在全球老化人口中，正显着推动眼科产业的成长。人口老化趋势导致青光眼和白内障等老龄化相关眼疾的发生率不断上升，从而对用于眼压控制和术后护理的处方眼药水产生了持续的需求。这确保了治疗方案拥有稳定的患者群体。根据爱尔康公司于2025年2月发布的2024年度报告，其视力保健部门的净销售额达到约43亿美元。此外，《视觉星期一》在2025年2月报道称，博士伦公司的总收入为47.9亿美元，这进一步证实了市场对综合眼科护理产品的持续需求。

市场挑战

严格的监管合规和品质保证通讯协定是全球眼药水产业发展的主要障碍。由于这些产品需直接作用于敏感的眼表，监管机构对其无菌标准与注射剂相同。这要求生产商维持复杂且资本密集的生产环境，并经历漫长的临床检验程序。这些进入障碍和高昂的营运门槛必然推高研发成本，减缓产品创新，并延缓新疗法的商业化进程。

未能遵守这些严格标准往往会导致监管干预和供应链中断。生产差异会导致产品召回和停产，造成市场供应严重缺口。根据美国卫生系统药剂师协会预测，2024年将出现创纪录的323种药品短缺，其中无菌眼科製剂由于持续存在的品管挑战，经常被认为是特别脆弱的类别。这些供应限制不仅直接缩小了市场规模和收入，还会削弱处方医生和患者的信心，从而限制整个行业的成长潜力。

市场趋势

随着企业将眼表健康置于优先地位，多剂量、无防腐剂包装技术的广泛应用正在改变製药业。由于传统配方通常使用苯扎氯铵等防腐剂，而这些防腐剂会伤害上皮组织，因此企业正在转向使用无需添加剂即可确保无菌的复杂给药系统。这种转变有效地结合了瓶装眼药水的便利性和单剂量管瓶的安全性。根据Aptar Pharma于2025年2月发布的“2024财年第四季及全年业绩报告”，其专有的药物输送系统部门（包括眼科挤压式给药器）在2024财年全年实现了9%的销售额增长。这反映了业界对先进容器密封系统日益增长的需求。

同时，脂质基和奈米乳剂配方的出现正在改变蒸发干眼症和睑板腺功能障碍的治疗方法。与仅补充水层的标准水溶液不同，这些创新治疗方法作用于泪膜的脂质层，防止泪液蒸发，从而从根本上解决大多数干眼症的原因。这种独特的治疗策略使其迅速获得商业性成功，製造商不断推出无水和富含脂质的溶液。例如，博士伦公司在2025年2月发布的「2024年第四季及全年业绩报告」中指出，其新型脂​​质处方眼药水Meevo第四季销售额达到约5,300万美元，显示泪液蒸发治疗药物已显着占领市场。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球眼药水市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（处方药与非处方药）
  • 依药物类别（抗过敏药、抗青光眼药、抗发炎药、抗 VEGF 药、其他）
  • 依疾病分类（眼部过敏、青光眼、眼部感染疾病、干眼症、视网膜疾病）
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美眼药水市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲眼药水市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区眼药水市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲眼药水市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲眼药水市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球眼药水市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Johnson & Johnson Inc.
• Genentech, Inc.
• Alcon Inc.
• Pfizer, Inc.
• Bausch Health Companies, Inc.
• Bayer Corporation
• Allergan, Inc.
• Abbott Laboratories, Inc.
• KC Pharmaceuticals, Inc.
• Akorn, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Eye Drop market is projected to expand from USD 16.12 Billion in 2025 to USD 23.11 Billion by 2031, registering a CAGR of 6.19%. Eye drops, characterized as sterile liquid pharmaceuticals applied to the ocular surface, are crucial for managing various conditions, including glaucoma, conjunctivitis, and dry eye disease. The industry is largely bolstered by the growing prevalence of age-related ocular disorders and the pervasive use of digital screens, which intensifies ocular surface complications. Data from the American Optometric Association in 2024 revealed that over 104 million working-age Americans spend more than seven hours daily on digital devices, a habit directly linked to increased eye strain and dryness, thereby sustaining demand for both over-the-counter lubricants and prescription ophthalmic treatments.

However, the market faces substantial hurdles regarding strict regulatory compliance and quality assurance. Regulatory authorities mandate rigorous sterility and safety protocols for ophthalmic products, requiring intricate manufacturing systems and extensive clinical validation prior to market approval. Consequently, manufacturers contend with high compliance costs and the inherent risk of product recalls, which can disrupt supply chains and damage consumer trust. These regulatory challenges serve as a significant restraint, potentially slowing the introduction of new formulations to patients and limiting the overall expansion of the sector.

Market Driver

The rising incidence of digital eye strain and dry eye syndrome acts as a primary catalyst for the Global Eye Drop market. Modern lifestyles involving prolonged exposure to digital screens have triggered a sharp increase in ocular surface diseases, necessitating the frequent use of artificial tears and lubricating drops. This trend is further intensified by environmental stressors and the growing use of contact lenses, which contribute to tear film instability. Manufacturers are meeting this need with targeted therapies, as reflected in strong financial results; for instance, Bausch + Lomb's February 2025 "Fourth-Quarter and Full-Year 2024 Results" announcement indicated that their dry eye portfolio revenue is nearing $1 billion, highlighting the urgent consumer demand for effective symptom relief.

Simultaneously, the increasing prevalence of chronic ophthalmic disorders, especially within the aging global population, significantly fuels industry growth. As demographic trends shift toward an older society, incidence rates of age-related conditions such as glaucoma and cataracts rise, creating a continuous demand for prescription eye drops for intraocular pressure management and post-surgical care. This ensures a stable patient base for therapeutic solutions. According to Alcon's "2024 Annual Report" from February 2025, the Vision Care franchise generated approximately $4.3 billion in net sales. Furthermore, Vision Monday reported in February 2025 that Bausch + Lomb achieved total revenue of $4.79 billion, underscoring the enduring necessity for comprehensive eye health products.

Market Challenge

Stringent regulatory compliance and quality assurance protocols constitute a major impediment to the advancement of the global eye drop industry. Given that these products are administered to the sensitive ocular surface, regulators enforce sterility standards comparable to those for injectable medications. This necessitates that manufacturers maintain complex, capital-intensive production environments and navigate protracted clinical validation procedures. These high barriers to entry and operation inevitably inflate development costs, decelerate product innovation, and delay the commercialization of new therapeutic options.

Failure to strictly adhere to these precise standards often leads to regulatory interventions that interrupt the supply chain. Manufacturing inconsistencies can result in product recalls and production stoppages, causing significant gaps in market availability. According to the American Society of Health-System Pharmacists, a record 323 active drug shortages were reported in 2024, with sterile ophthalmic preparations frequently cited as a vulnerable category due to ongoing quality management difficulties. These supply constraints directly reduce market volume and revenue while undermining the confidence of prescribers and patients, thereby limiting the sector's broader growth potential.

Market Trends

The widespread adoption of multi-dose preservative-free packaging technologies is reshaping manufacturing as companies prioritize ocular surface health. Traditional formulations often utilize preservatives like benzalkonium chloride that can damage the epithelium, prompting a transition toward complex dispensing systems that ensure sterility without additives. This shift effectively combines the convenience of bottled eye drops with the safety profile of unit-dose vials. According to Aptar Pharma's February 2025 "Fourth Quarter and Annual 2024 Results," the segment responsible for proprietary drug delivery systems, including ophthalmic squeeze dispensers, achieved 9% sales growth for the full year 2024, reflecting the industrial surge toward these advanced container closure systems.

Concurrently, the emergence of lipid-based and nano-emulsion formulations is transforming the treatment of evaporative dry eye and Meibomian Gland Dysfunction. Unlike standard aqueous solutions that only replenish the water layer, these innovative therapies target the tear film's lipid layer to prevent evaporation, addressing the root cause of most dry eye cases. This specific therapeutic focus has gained rapid commercial traction as manufacturers launch water-free and lipid-enhanced solutions. For example, Bausch + Lomb's February 2025 "Fourth-Quarter and Full-Year 2024 Results" announcement reported approximately $53 million in fourth-quarter sales for Miebo, a novel lipid-based prescription drop, highlighting the immediate market uptake of treatments addressing tear evaporation.

Key Market Players

• Johnson & Johnson Inc.
• Genentech, Inc.
• Alcon Inc.
• Pfizer, Inc.
• Bausch Health Companies, Inc.
• Bayer Corporation
• Allergan, Inc.
• Abbott Laboratories, Inc.
• KC Pharmaceuticals, Inc.
• Akorn, Inc.

Report Scope

In this report, the Global Eye Drop market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Eye Drop market, By Type

• Prescription v/s Over-the-Counter

Eye Drop market, By Drug Class

• Anti-allergy
• Anti-glaucoma
• Anti-inflammatory
• Anti-VEGF
• Others

Eye Drop market, By Disease Indication

• Eye Allergy
• Glaucoma
• Eye Infections
• Dry Eye Diseases
• Retinal Disorders

Eye Drop market, By Distribution Channel

• Hospitals Pharmacy
• Retail Pharmacy
• Online Pharmacy

Eye Drop market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Eye Drop market.

Available Customizations:

Global Eye Drop market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Eye Drop market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Prescription v/s Over-the-Counter)
  • 5.2.2. By Drug Class (Anti-allergy, Anti-glaucoma, Anti-inflammatory, Anti-VEGF, Others)
  • 5.2.3. By Disease Indication (Eye Allergy, Glaucoma, Eye Infections, Dry Eye Diseases, Retinal Disorders)
  • 5.2.4. By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Eye Drop market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Disease Indication
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Eye Drop market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Disease Indication
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Eye Drop market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Disease Indication
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Eye Drop market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Disease Indication
      • 6.3.3.2.4. By Distribution Channel

7. Europe Eye Drop market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Disease Indication
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Eye Drop market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Disease Indication
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Eye Drop market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Disease Indication
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Eye Drop market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Disease Indication
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Eye Drop market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Disease Indication
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Eye Drop market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Disease Indication
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Eye Drop market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Disease Indication
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Eye Drop market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Disease Indication
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Eye Drop market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Disease Indication
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Eye Drop market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Disease Indication
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Eye Drop market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Disease Indication
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Eye Drop market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Disease Indication
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Eye Drop market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Disease Indication
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Eye Drop market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Disease Indication
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Eye Drop market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Disease Indication
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Eye Drop market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Disease Indication
      • 9.3.3.2.4. By Distribution Channel

10. South America Eye Drop market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Disease Indication
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Eye Drop market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Disease Indication
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Eye Drop market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Disease Indication
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Eye Drop market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Disease Indication
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Eye Drop market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Johnson & Johnson Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Genentech, Inc.
• 15.3. Alcon Inc.
• 15.4. Pfizer, Inc.
• 15.5. Bausch Health Companies, Inc.
• 15.6. Bayer Corporation
• 15.7. Allergan, Inc.
• 15.8. Abbott Laboratories, Inc.
• 15.9. KC Pharmaceuticals, Inc.
• 15.10. Akorn, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer